Biodextris
Isaac Haq is a seasoned professional in the investment and life sciences sectors, currently serving as a Board Member and Portfolio Management Lead at Biodextris and contributing to the Investment Team at ArchiMed since 2018, where roles have progressed from Analyst to Associate Director. Additionally, Isaac held the position of Head of Strategy & Corporate Development at Pluristyx, Inc. during a sabbatical from ArchiMed, focusing on iPSC-based technologies. Experience includes serving as a Board Observer for multiple companies, such as Polyplus-transfection S.A., Xpress Biologics, and CLEAN BIOLOGICS. Previous roles include Junior Analyst at Motive Partners and Business Development Junior Analyst at Biotechspert. Isaac Haq holds a BA in Medicine with Cognitive Neuroscience from the University of Cambridge, an MSc in Finance and Private Equity from The London School of Economics and Political Science, and is pursuing a PhD in Health Economics & Policy at Lancaster University.
This person is not in any teams
This person is not in any offices
Biodextris
Follow us for the latest on our expansion, job opportunities and the latest relevant news in our space! Biodextris is comprised of experienced product development scientist located in Laval (Montreal), Quebec. The group has worked together since 2002, as part of ID Biomedical and later GSK-Vaccines. We have developed numerous products for all phases of clinical development for programs conducted in the US, Canada and Europe. Companies choose to work with us because we are experts in developing complete analytical packages for novel and complex products. Companies trust us to accelerate their project from the bench to the clinic by delivering robust and reliable production processes ready for manufacturing. Companies rely on our Quality Control testing services for their clinical phase vaccines and biologics. We look forward to sharing this expertise with you.